TY - JOUR
T1 - Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy
T2 - A Post Hoc Analysis of the POINT Trial
AU - Grory, Brian Mac
AU - Piccini, Jonathan P.
AU - Yaghi, Shadi
AU - Poli, Sven
AU - De Havenon, Adam
AU - Rostanski, Sara K.
AU - Weiss, Martin
AU - Xian, Ying
AU - Johnston, S. Claiborne
AU - Feng, Wuwei
N1 - Publisher Copyright:
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - BACKGROUND: One-quarter of all strokes are subsequent events. It is not known whether higher levels of blood glucose are associated with an increased risk of subsequent stroke after high-risk transient ischemic attack or minor ischemic stroke. METHODS AND RESULTS: We performed a secondary analysis of the POINT (Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial to evaluate the relationship between serum glucose hyperglycemia (≥180 mg/dL) versus normoglyce-mia (<180 mg/dL) before enrollment in the trial and outcomes at 90 days. The primary end point was subsequent ischemic stroke modeled by a multivariable Cox model with adjustment for age, sex, race, ethnicity, study treatment assignment, index event, and key comorbidities. Of 4878 patients included in this study, 267 had a recurrent stroke. There was a higher hazard of subsequent stroke in patients with hyperglycemia compared with normoglycemia (adjusted hazard ratio [HR], 1.50 [95% CI, 1.05–2.14]). Treatment with dual antiplatelet therapy was not associated with a reduced hazard of subsequent stroke in patients with hyperglycemia (HR, 1.18 [95% CI, 0.69–2.03]), though the wide confidence interval does not exclude a treatment effect. When modeled as a continuous variable, there was evidence of a nonlinear association between serum glucose and the hazard of subsequent stroke (P<0.001). CONCLUSIONS: Hyperglycemia on presentation is associated with an increased risk of subsequent ischemic stroke after high-risk transient ischemic attack or minor stroke. A rapid, simple assay of serum glucose may be a useful biomarker to identify patients at particularly high risk of subsequent ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT0099102.
AB - BACKGROUND: One-quarter of all strokes are subsequent events. It is not known whether higher levels of blood glucose are associated with an increased risk of subsequent stroke after high-risk transient ischemic attack or minor ischemic stroke. METHODS AND RESULTS: We performed a secondary analysis of the POINT (Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial to evaluate the relationship between serum glucose hyperglycemia (≥180 mg/dL) versus normoglyce-mia (<180 mg/dL) before enrollment in the trial and outcomes at 90 days. The primary end point was subsequent ischemic stroke modeled by a multivariable Cox model with adjustment for age, sex, race, ethnicity, study treatment assignment, index event, and key comorbidities. Of 4878 patients included in this study, 267 had a recurrent stroke. There was a higher hazard of subsequent stroke in patients with hyperglycemia compared with normoglycemia (adjusted hazard ratio [HR], 1.50 [95% CI, 1.05–2.14]). Treatment with dual antiplatelet therapy was not associated with a reduced hazard of subsequent stroke in patients with hyperglycemia (HR, 1.18 [95% CI, 0.69–2.03]), though the wide confidence interval does not exclude a treatment effect. When modeled as a continuous variable, there was evidence of a nonlinear association between serum glucose and the hazard of subsequent stroke (P<0.001). CONCLUSIONS: Hyperglycemia on presentation is associated with an increased risk of subsequent ischemic stroke after high-risk transient ischemic attack or minor stroke. A rapid, simple assay of serum glucose may be a useful biomarker to identify patients at particularly high risk of subsequent ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT0099102.
KW - antithrombotic therapy
KW - clinical trial
KW - diabetes
KW - hyperglycemia
KW - ischemic stroke
UR - http://www.scopus.com/inward/record.url?scp=85123969648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123969648&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.023223
DO - 10.1161/JAHA.121.023223
M3 - Article
C2 - 35043692
AN - SCOPUS:85123969648
SN - 2047-9980
VL - 11
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 3
M1 - e023223
ER -